Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis

NCT03703102 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

274

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: KHK4083
DRUG: Placebo

Sponsor

Kyowa Kirin, Inc.

Collaborators

[object Object]